Impact of Genomics on Disparities in Breast Cancer Radiosensitivity

基因组学对乳腺癌放射敏感性差异的影响

• 批准号: 8403713
• 负责人: Jennifer J Hu
• 金额: $ 49.71万
• 依托单位: UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-01-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8403713
• 关键词: Acute; Adjuvant Radiotherapy; Adverse effects; Adverse reactions; African American; American; Amino Acid Sequence; Amino Acids; Angiogenesis Pathway; Apoptosis; Benefits and Risks; Biological Assay; Biological Markers; Breast; Cancer Etiology; Cancer Patient; Cell Cycle; Cell Cycle Regulation; Cessation of life; Clinical; Clinical Treatment; Comet Assay; Cosmetics; DNA Damage; DNA Repair; Data; Development; Developmental Process; Disease; Edema; Epidemiologist; Ethnic group; Evaluation; Follow-Up Studies; Funding; Genes; Genetic; Genetic Models; Genetic Variation; Genomics; Goals; Hispanics; Immunology; Individual; Inflammation; Intensity-Modulated Radiotherapy; Interdisciplinary Study; Intervention; Ionizing radiation; Knowledge; Late Effects; Lead; Learning; Logit Models; Malignant Neoplasms; Minority; Modeling; Molecular; Mutation; Normal tissue morphology; Not Hispanic or Latino; Oncologist; Outcome; Pain; Pathway interactions; Patients; Peptide Sequence Determination; Phenotype; Phosphorylation; Population; Population Study; Positioning Attribute; Postoperative Period; Progression-Free Survivals; Quality of life; Radiation Oncologist; Radiation Tolerance; Radiation therapy; Reaction; Recruitment Activity; Recurrence; Research; Resistance; Sampling; Second Primary Cancers; Signal Transduction; Single Nucleotide Polymorphism; Skin; Staging; Surgeon; Target Populations; Testing; Trees; Underserved Population; Woman; Work; breast lumpectomy; cancer diagnosis; cancer health disparity; cancer risk; cell motility; cohort; data mining; design; dosimetry; effective intervention; effective therapy; experience; follow-up; functional genomics; gene interaction; genetic analysis; genome-wide; high risk; high throughput technology; improved; indexing; intercellular communication; malignant breast neoplasm; medically underserved population; mortality; outcome forecast; racial and ethnic; response; standard care; tool; treatment strategy; tumor

PROJECT SUMMARY/ABSTRACT Breast cancer is the most frequently diagnosed cancer and the second leading cause of cancer death in American women. Lumpectomy followed by radiotherapy (RT) has significantly improved survival. However, about 30% of patients develop a Grade 2 or worse early or late skin reaction, pain, breast edema and poor cosmetic results that impact quality of life. Inter-individual variability in the development of RT-induced adverse reactions in normal tissue is well-documented for both acute and late effects. African-American (AA) and underserved populations are less likely than Whites to receive the recommended adjuvant RT, if treated, have a higher risk for developing RT-related side effects and worse clinical outcome. To achieve our long-term goals in improving quality of life, clinical outcome, and overcoming breast cancer disparities, we will use a genome- wide approach to test genomic prediction models for RT-induced adverse reactions and recurrence in three racial/ethnic populations. We will test a new paradigm that multiple genetic variations and functional phenotypes contribute to radiation sensitivity that may predict RT-induced side effects and clinical outcome. Investigating this new paradigm will develop powerful tools in identifying high-risk populations and targets for personalized intervention and treatment. Aim 1 will evaluate polygenic models of RT-induced early adverse skin reactions (EASRs) in 1000 breast cancer patients with a comprehensive evaluation of genome-wide nonsynonymous single nucleotide polymorphisms (nsSNPs; n=21,877). Aim 2 will evaluate the association between RT-induced EASRs and three functional DNA damage/repair phenotypes. Aim 3 will develop polygenic models of genome-wide nsSNPs in predicting RT-induced late side effects and/or recurrence in a breast cancer cohort of 850 women with a median follow up of 8 years (range 4-12 years). The outcome of the proposed research will advance our scientific knowledge in the accurate assessment of prognosis in cancer patients, which is crucial to controlling the suffering and death due to breast cancer. Prediction models provide an important approach to assessing cancer risk, progression, quality of life, and prognosis. These prediction models may identify individuals at high risk of developing adverse reactions or recurrence who may benefit from targeted treatment or other interventions. They also may enable the development of benefit-risk indices that will aid in the design and planning of clinical treatment. The proposed research will use a hypothesis- driven approach to integrate genetic and functional biomarkers in developing optimal prediction models of RT- induced adverse reactions and recurrence. The outcome will target effective intervention and treatment strategies, and ultimately improve quality of life and progression-free survival in breast cancer patients, particularly in minority and underserved populations with more aggressive disease and worse clinical outcome. This will be the largest and most complete genetic analysis of RT-related clinical outcome to date, and will move the field significantly towards the goal of more effective, personalized therapy for breast cancer patients.

项目概要/摘要 乳腺癌是最常诊断的癌症，也是癌症死亡的第二大原因 在美国女性中。肿瘤切除术后进行放射治疗（RT）可显着提高生存率。然而， 约30%的患者出现2级或更严重的早期或晚期皮肤反应、疼痛、乳房水肿和不良反应 影响生活质量的美容效果。放疗引起的不良反应发生的个体差异 正常组织中的急性反应和迟发反应都有详细记录。非裔美国人 (AA) 和 服务不足的人群接受推荐的辅助放疗的可能性低于白人，如果接受治疗的话， 发生放疗相关副作用和临床结果较差的风险更高。实现我们的长期目标 在改善生活质量、临床结果和克服乳腺癌差异方面，我们将使用基因组 测试放疗引起的不良反应和复发的基因组预测模型的广泛方法 种族/族裔人口。我们将测试一种新的范式，即多种遗传变异和功能 表型有助于辐射敏感性，可以预测放疗引起的副作用和临床结果。 研究这一新范式将开发出强大的工具来识别高风险人群和目标 个性化干预和治疗。目标 1 将评估 RT 诱导的早期不良反应的多基因模型 对 1000 名乳腺癌患者的皮肤反应（EASR）进行全基因组综合评估 非同义单核苷酸多态性（nsSNP；n=21,877）。目标 2 将评估协会 RT 诱导的 EASR 与三种功能性 DNA 损伤/修复表型之间的关系。目标3将发展 全基因组 nsSNP 的多基因模型可预测放疗引起的晚期副作用和/或复发 乳腺癌队列由 850 名女性组成，中位随访时间为 8 年（范围 4-12 年）。的结果 拟议的研究将提高我们在准确评估癌症预后方面的科学知识 患者，这对于控制乳腺癌造成的痛苦和死亡至关重要。预测模型提供 评估癌症风险、进展、生活质量和预后的重要方法。这些预测 模型可以识别出现不良反应或复发的高风险个体，这些个体可能会受益 来自针对性治疗或其他干预措施。它们还可以促进效益风险指数的开发 这将有助于临床治疗的设计和规划。拟议的研究将使用一个假设 - 整合遗传和功能生物标志物的驱动方法，开发 RT 的最佳预测模型 诱发不良反应和复发。结果将针对有效的干预和治疗 策略，最终改善乳腺癌患者的生活质量和无进展生存期， 特别是在少数群体和服务不足的人群中，他们的疾病更具侵袭性，临床结果更差。 这将是迄今为止最大、最完整的放疗相关临床结果的基因分析，并将 显着推动该领域朝着为乳腺癌患者提供更有效、个性化治疗的目标迈进。